Non-Invasive Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030

Non-Invasive Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030

Non-Invasive Cancer Diagnostic Trends and Forecast

The future of the global non-invasive cancer diagnostic market looks promising with opportunities in the solid tumors, blood cancer, lung cancer, and breast cancer markets. The global non-invasive cancer diagnostic market is expected to reach an estimated $199.2 billion by 2030 with a CAGR of 6.8% from 2024 to 2030. The major drivers for this market are rising concerns of chronic cancer, introduction of advanced bio marker based detection methods,and supportive government initiative to promote the use of non-invasive diagnostic test.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Non-Invasive Cancer Diagnostic by Segment

The study includes a forecast for the global non-invasive cancer diagnostic by therapeutics, technology, end use industry, technology, and region

Non-Invasive Cancer Diagnostic Market by Therapeutics [Shipment Analysis by Value from 2018 to 2030]:

• Solid Tumors
• Blood Cancer
• Lung Cancer
• Breast Cancer
• Others

Non-Invasive Cancer Diagnostic Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

• Clinical Chemistry
• Immunochemistry
• Molecular Diagnostics
• Others

Non-Invasive Cancer Diagnostic Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Non-Invasive Cancer Diagnostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies non-invasive cancer diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the non-invasive cancer diagnostic companies profiled in this report include-

• Precision Therapeutics
• A&G Pharmaceutical
• Affymetrix
• AVIVA Biosciences
• BIOVIEW
• Laboratory Corporation Of America
• Quest Diagnostics Incorporated Cancer Genetics
• Digene
• Gen-Probe
• IVDiagnostics

Non-Invasive Cancer Diagnostic Market Insights

Lucintel forecast that clinical chemistry is expected to witness highest growth over the forecast period due to its various advantages, including highly sensitive, low cost, and widespread availibility.

Breast cancer will remain the largest segment due to increasing number of breast cancer patients around the world.

North America is expected to witness highest growth over the forecast period due to existence of well-established health infrastructure, growing prevalence of cancer related cases among people, and presence of key players in the region.

Features of the Global Non-Invasive Cancer Diagnostic Market

Market Size Estimates: Non-invasive cancer diagnostic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Non-invasive cancer diagnostic market size by therapeutics, technology, and region in terms of value ($B).

Regional Analysis: Non-invasive cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapeutics, technology, and regions for the non-invasive cancer diagnostic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the non-invasive cancer diagnostic market.

Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q.1 What is the non-invasive cancer diagnostic market size?

Answer: The global non-invasive cancer diagnostic market is expected to reach an estimated $199.2 billion by 2030.

Q.2 What is the growth forecast for non-invasive cancer diagnostic market?

Answer: The global non-invasive cancer diagnostic market is expected to grow with a CAGR of 6.8% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the non-invasive cancer diagnostic market?

Answer: The major drivers for this market are rising concerns of chronic cancer, introduction of advanced bio marker based detection methods, and supportive government initiative to promote the use of non-invasive diagnostic test.

Q4. What are the major segments for non-invasive cancer diagnostic market?

Answer: The future of the non-invasive cancer diagnostic market looks promising with opportunities in the solid tumors, blood cancer, lung cancer, and breast cancer markets.

Q5. Who are the key non-invasive cancer diagnostic market companies?

Answer: Some of the key non-invasive cancer diagnostic companies are as follows:

• Precision Therapeutics
• A&G Pharmaceutical
• Affymetrix
• AVIVA Biosciences
• BIOVIEW
• Laboratory Corporation of America
• Quest Diagnostics Incorporated Cancer Genetics
• Digene
• Gen-Probe
• IVDiagnostics

Q6. Which non-invasive cancer diagnostic market segment will be the largest in future?

Answer: Lucintel forecast that clinical chemistry is expected to witness highest growth over the forecast period due to its various advantages, including highly sensitive, low cost, and widespread availibility.

Q7. In non-invasive cancer diagnostic market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to existence of well-established health infrastructure, growing prevalence of cancer related cases among people, and presence of key players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the non-invasive cancer diagnostic market by therapeutics (solid tumors, blood cancer, lung cancer,breast cancer, and others), technology (clinical chemistry, immunochemistry, molecular diagnostics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2. Which segments will grow at a faster pace and why?

Q.3. Which region will grow at a faster pace and why?

Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?

Q.5. What are the business risks and competitive threats in this market?

Q.6. What are the emerging trends in this market and the reasons behind them?

Q.7. What are some of the changing demands of customers in the market?

Q.8. What are the new developments in the market? Which companies are leading these developments?

Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?

Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?

Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Please note: It will take 2-3 business days to deliver the report upon receipt the order.